The PRV is not needed for either trof or 2591 in the current known indications as they are all orphan diseases and already get fast tracked. it would make no sense for acadia to waste $66 million to save paying NEU $33 million.
Big pharma will only be interested in North american rights which is the low hanging fruit with the ROW being a cherry on top (to mix metaphors) once you own North america. The ROW alone is not worth much alone and is too complicated with the multiple jurisdictions. So I cant see 2 pharmaceutical companies developing 2591 unless it is a deal like Neu struck with acadia. Thats just not going to happen this time.
in addition the likelihood of Acadia stymying future indications is far fetched as they will need to prove that they are already doing animal studies in the said new indication at the time NEU announces.
The only logical reason for the recent sell off is if the Angelman results have leaked and are negative although I would have expected bigger volumes. I am personally backing 2591 in and have just bought more.
NEU Price at posting:
$19.34 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)